FEATURE ARTICLES
Pharmaceutical innovation is making drug manufacturing more complex—and placing new demands on facility design. Accommodating today’s processes is no longer enough. Facilities must also be able to change. Modular design offers a way to build that adaptability into the facility itself.
- Why Early Evaluation Of Process Parameters Matters In OSD Scale-Up
- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
- Is Your Supply Chain Ready For The End Of Class VI?
- Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma
- Capturing Tablet Disintegration for Improved OSD Development
- Beyond API Sourcing: Avoiding Supply Disruptions For Small Molecule Drugs
- Why We Need Pharmaceutical Engineering Project Management As A Distinct Discipline
PHARMA ONLINE WHITE PAPERS
-
From Open Cleanrooms To Closed Systems – What Is Driving The Change?
Aseptic processing is evolving. Regulatory changes and technological advancements are driving a shift from open cleanrooms to closed systems for sterile drug manufacturing.
-
For Greater Transparency And Efficiency7/21/2026
Paper-heavy production can slow decisions and limit flexibility. See how IT/OT integration connects shop-floor and enterprise data to support real-time visibility and more resilient operations.
-
Where Speed Meets Complexity In Bioprocess Development6/18/2026
Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.
-
Beyond Flexibility: The Strategic Value Of Single-Use In Virus Filtration7/24/2026
Single-use virus filtration offers key strategic benefits beyond operational convenience, enabling faster time to market, scalable manufacturing, and flexible supply chains for biopharma production.
-
Get More From Less: AMP Chemistry Outperforms Hybrid Capture6/9/2026
Sequencing performance can drop quickly with low-quality, low-input FFPE DNA. Gain insight into how one approach helps labs minimize repeats and maintain more consistent results.
-
Chemoenzymatic N-glycan Conjugation Of Native mAbs Provides Homogeneous, Efficacious ADCs9/3/2026
A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.
PHARMA ONLINE APP NOTES & CASE STUDIES
- How LIMS Supports QC Scaling At Forge Biologics
- Leverage Apps To Reduce Line Changeover Time From 14 Days To 3
- Organ-On-A-Chip Technology Unlocks Patient-Derived Precision Medicine
- 3D Screen Printing: Enabling A New Generation Of Complex Formulations
- Development Of Separation Methods For GLP-1 Synthetic Peptides
NEWSLETTER ARCHIVE
- 10.30.26 -- Software Solutions To Streamline Pharmaceutical Operations
- 10.30.26 -- Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma
- 10.30.26 -- What's Being Overlooked In Biopharma Manufacturing?
- 10.29.26 -- Early Developability Assessment Reduces Risk In Multi-Specific Antibody Programs
- 10.29.26 -- Capturing Tablet Disintegration For Improved OSD Development
- Designing Pharma Facilities For Change, Not Just Capacity
- Why Early Evaluation Of Process Parameters Matters In OSD Scale-Up
- Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma
- Capturing Tablet Disintegration for Improved OSD Development
- Why CMC Tech Transfer Should Begin With The End In Mind
INDUSTRY NEWS
-
Let Your Voice Help Shape Pharma Manufacturing
Pharmaceutical Online hosts live virtual panels with industry experts on important topics and challenges, and we want to know what topics are important to you. Please consider taking a few minutes of your time to tell us what they are.
-
ISPE Announces 2026 FOYA Winners
These awards recognize pharmaceutical and biopharmaceutical manufacturing projects that demonstrate excellence across innovation, operations, supply chain, Pharma 4.0, and social impact.
-
Høeg In, Pazdur Out At The FDA
What an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
EDITORIAL COLLECTIONS
Our curated Editorial Collections bring expert insights together in one place, offering practical perspectives and actionable guidance to help you navigate complex decisions and improve performance.
More Editorial CollectionsSUPPLIER NEWS
-
Lonza Further Expands Bioconjugation Manufacturing To Support Growing ADC Demand10/29/2026
Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today the further expansion of its integrated bioconjugation manufacturing offering. Lonza is combining the flexibility of mid-scale bioconjugation manufacturing with its previously announced large-scale bioconjugation expansion in Visp (CH), which will now include three multiproduct suites. Together, these capabilities will offer customers a scalable manufacturing pathway from clinical development through commercial supply for antibody-drug conjugates (ADCs) and other bioconjugates.
-
Ardena Launches Online Biomarker Catalogue: 228 Markers, One Quote Request10/29/2026
Ardena has launched a searchable Biomarker Catalogue on its website, giving sponsors a faster route from biomarker selection to a bioanalysis quote.
-
Meissner Hosts Ribbon Cutting Ceremony For X-Ray Irradiation Services And Breaks Ground On Phase 2 Of Its Athens, Georgia, U.S.A. Campus10/23/2026
Meissner Corporation, a leading manufacturer of advanced microfiltration and therapeutic manufacturing systems for biopharmaceutical production of life-saving and life enhancing medicines, celebrated a double milestone in Athens-Clarke County: the ribbon cutting for its new X-ray irradiation services facility and the groundbreaking for Phase 2 of its Athens, Georgia, U.S.A., manufacturing campus.
-
Global Pharma Manufacturing Community Meets In Berlin For PHARMAP 202710/22/2026
Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027 to address the growing disconnect between investment and outcomes. The closed-door format, supported by Host Sponsor Bayer AG, fosters direct dialogue between pharmaceutical companies, contract manufacturing organisations and service providers, creating space for ongoing discussions that move beyond theory and deliver actionable solutions.
-
LGM Pharma Acquires Sannova Analytical, Expanding cGMP Analytical And GLP Bioanalytical Services10/22/2026
LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and drug development services, today announced it has acquired Sannova Analytical, a contract research laboratory headquartered in Somerset, N.J. The acquisition expands LGM Pharma’s analytical testing services business by adding Good Laboratory Practice (GLP) bioanalysis, including peptide and oligonucleotide testing, and by bringing genotoxic and nitrosamine impurity testing, extractables and leachables evaluations, and additional elemental impurities testing to LGM Pharma’s existing cGMP analytical services. Sannova will continue to operate under its own name as Sannova Analytical, led by its current management team.

